Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Dare Bioscience Inc (NASDAQ: DARE) is a clinical-stage biopharmaceutical leader advancing innovative therapies for women’s reproductive and sexual health. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Track the latest developments across DARE’s pipeline of non-hormonal contraceptives, sexual health treatments, and cervical health solutions. Our curated news collection includes updates on FDA submissions, trial results for candidates like Ovaprene® and Sildenafil Cream 3.6%, and collaborations advancing women’s healthcare innovation.
Key focus areas include progress toward addressing unmet needs in bacterial vaginosis treatment, female sexual arousal disorder (FSAD), and HPV-related cervical conditions. Bookmark this page for real-time access to earnings announcements, research publications, and licensing agreements that shape DARE’s position in the biopharma sector.
Daré Bioscience presented positive results from the DARE-BVFREE Phase 3 trial for DARE-BV1, targeting bacterial vaginosis in women. The study met its primary endpoint, achieving clinical cure rates between 70-81% with a single vaginal dose. This investigational hydrogel formulation includes clindamycin phosphate 2% and aims to provide a convenient alternative to current treatments. The company submitted a new drug application to the FDA in June 2021 and shared findings at the Controlled Release Society Annual Meeting on July 27, 2021.
Daré Bioscience, Inc. (NASDAQ: DARE) has entered into a Cooperative Research and Development Agreement (CRADA) with the NICHD for the Phase 3 study of Ovaprene®, a hormone-free monthly contraceptive. This collaboration will enable shared funding and expertise in conducting the pivotal study, which is expected to begin in 2022. Daré will contribute $5.5 million towards the study costs and aims to submit an Investigational Device Exemption (IDE) to the FDA in Q4 2021. If approved, Ovaprene could become the first monthly non-hormonal contraceptive for women.
Daré Bioscience (NASDAQ: DARE) announced positive topline results from its Phase 1 clinical trial of DARE-HRT1, a novel intravaginal ring (IVR) delivering bio-identical estradiol and progesterone. The trial demonstrated successful continuous delivery over 28 days, targeting vasomotor symptoms and vaginal issues associated with menopause. This positions DARE-HRT1 to potentially be the first FDA-approved combined hormonal therapy in a monthly format. Encouragingly, the treatment was well-tolerated, with high acceptability among participants.
Daré Bioscience (NASDAQ: DARE) will present at the 2021 BIO Digital virtual event from June 10-11 and 14-18, 2021. CEO Sabrina Martucci Johnson will discuss the company's portfolio of innovative investigational products beginning June 10 at 9 a.m. ET. The presentation will be accessible to registered attendees on-demand. Following the event, a recording will be available on Daré's investor relations website until July 2, 2021. Daré is focused on advancing women's health through unique products, including Ovaprene® and Sildenafil Cream, among others.
Daré Bioscience (NASDAQ: DARE) announced its financial results for Q1 2021, reporting a comprehensive loss of approximately $7.3 million, up from $4.3 million in Q1 2020. The company has $7.7 million in cash and cash equivalents. Daré plans to submit a New Drug Application for DARE-BV1, a treatment for bacterial vaginosis, in Q2 2021. Additionally, the Phase 2b study for Sildenafil Cream, aimed at treating female sexual arousal disorder, has commenced. The company also targets several key milestones for 2021-2022 across its product portfolio.
Daré Bioscience, Inc. (NASDAQ: DARE) will host a conference call and live webcast on May 13, 2021, at 4:30 p.m. ET to discuss its financial results for Q1 2021 and provide updates on the company. Interested participants can join via phone or through a webcast on the company’s investor relations website. Daré is focused on innovating women's health products, including candidates for contraception, sexual arousal disorder, bacterial vaginosis, and hormone therapy for menopause.
Daré Bioscience, Inc. (NASDAQ:DARE) announced that results from its postcoital test (PCT) clinical study of Ovaprene, a hormone-free monthly intravaginal contraceptive, will be presented at the 2021 ACOG Annual Meeting from April 30 to May 2, 2021. The topline results indicate Ovaprene effectively prevented motile sperm from entering the cervical canal. Medical Director, Christine Mauck, expressed confidence in advancing to a pivotal effectiveness study pending FDA approval. The virtual presentation will be accessible on the ACOG website starting April 30, 2021.
Daré Bioscience, Inc. (NASDAQ:DARE) announced positive topline results from its Phase 3 DARE-BVFREE study of DARE-BV1, a vaginal gel for treating bacterial vaginosis, set to be presented at the ACOG Annual Meeting from April 30 to May 2, 2021. The study involved 307 women, showing a clinical cure rate of 70% for the DARE-BV1 group compared to 36% for the placebo at Day 21-30. Notably, DARE-BV1 outperformed existing treatments in terms of efficacy and was well-tolerated with no adverse event-related discontinuations.
Daré Bioscience (NASDAQ: DARE) announced the appointment of Dr. Sophia N. Ononye-Onyia to its Board of Directors. Dr. Ononye-Onyia brings extensive experience in women's health commercialization, having held senior roles in global biopharmaceutical companies. Her leadership is expected to guide Daré's product candidates, including DARE-BV1, towards successful market entry. Dr. Ononye-Onyia is the founder of The Sophia Consulting Firm and has a strong background in medicinal chemistry and public health. This strategic appointment aims to enhance shareholder value.
Daré Bioscience (NASDAQ: DARE) reported its financial results for the year ending December 31, 2020. The company achieved a commercial partnership with Bayer for Ovaprene, potentially bringing in up to $310 million in milestone payments. The completion of its first Phase 3 study for DARE-BV1 showed a 76% clinical cure rate for bacterial vaginosis. Financially, the company reported a comprehensive loss of $27.4 million, with significant increases in R&D expenses. Cash equivalents were $4.7 million, with $29.5 million in net cash received during FY2020. Future objectives include NDA submissions and ongoing clinical trials.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
